Understanding why glioblastoma tumors resist treatment
Molecular determinants of cellular heterogeneity and therapeutic resistance in GBM.
This study is looking into why glioblastoma tumors can be tough to treat and how certain cells help them grow and resist treatment, with the hope of finding new ways to make treatments work better for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hugo W. Moser Res Inst Kennedy Krieger NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11030243 on NIH RePORTER |
What this research studies
This research investigates the molecular factors that contribute to the treatment resistance and diversity of glioblastoma (GBM) tumors. By utilizing advanced cell models and single-cell genomics, the team aims to uncover how glioma stem cells (GSCs) promote tumor growth and resist therapies. The study focuses on specific genes and mechanisms that may be targeted to improve treatment outcomes for patients with GBM. Ultimately, the goal is to identify new therapeutic targets that could lead to more effective treatments for this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing or have undergone standard treatments like surgery, radiation, or chemotherapy.
Not a fit: Patients with non-glioblastoma brain tumors or those who are not currently receiving treatment for glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies that improve survival rates and quality of life for patients with glioblastoma.
How similar studies have performed: Previous research has shown promise in targeting glioma stem cells and understanding their role in treatment resistance, indicating that this approach could yield significant insights.
Where this research is happening
Baltimore, United States
- Hugo W. Moser Res Inst Kennedy Krieger — Baltimore, United States (Active)
Researchers
- Principal investigator: Lopez-Bertoni, Hernando Martin — Hugo W. Moser Res Inst Kennedy Krieger
- Study coordinator: Lopez-Bertoni, Hernando Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.